Literature DB >> 12459712

The role of Stat5 in estrogen receptor-positive breast cancer.

Hiroko Yamashita1, Hirotaka Iwase.   

Abstract

Estrogen receptor (ER) has been a successful target for effective prevention and treatment strategies in breast cancer, whereas growth factors and their signaling molecules are proving to be effective treatment targets as well. Understanding the interaction between ER and growth factor signaling pathways should provide clues to optimal treatment approaches and new strategies to overcome and prevent endocrine resistance. Cross-talk between ER and signal transducer and activator of transcription 5 (Stat5) has also been reported. Stat5 regulates growth, differentiation, and survival of mammary and hematopoietic cells. The role of Stat5 in breast cancer has not been established, although Stat5 is critical for some hematopoietic malignancies. We have analyzed the role of Stat5 in the progression of ER-positive breast cancer cells such as T47D and MCF7 in which Stat5b is constitutively activated. Adenoviral-mediated dominant-negative Stat5 induced apoptosis in T47D cells but not in caspase-3 negative MCF7 cells. Our study indicates that targeting Stat5 may represent a new strategy to suppress estrogen receptor activity and induce apoptosis in Stat5-activated, ER-positive breast cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459712     DOI: 10.1007/bf02967610

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  8 in total

1.  Signal transducer and activator of transcription 3 and 5 regulate system Xc- and redox balance in human breast cancer cells.

Authors:  Katja Linher-Melville; Sina Haftchenary; Patrick Gunning; Gurmit Singh
Journal:  Mol Cell Biochem       Date:  2015-04-21       Impact factor: 3.396

2.  In vivo and in vitro estrogenic and progestagenic actions of Tibolone.

Authors:  Anil Sadarangani; Ana María Salgado; Sumie Kato; Mauricio Pinto; Andrés Carvajal; Carolina Monso; Gareth I Owen; Pilar Vigil
Journal:  Biol Res       Date:  2005       Impact factor: 5.612

Review 3.  Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.

Authors:  Kay-Uwe Wagner; Hallgeir Rui
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-29       Impact factor: 2.673

4.  Human dyskerin binds to cytoplasmic H/ACA-box-containing transcripts affecting nuclear hormone receptor dependence.

Authors:  Federico Zacchini; Giulia Venturi; Veronica De Sanctis; Roberto Bertorelli; Claudio Ceccarelli; Donatella Santini; Mario Taffurelli; Marianna Penzo; Davide Treré; Alberto Inga; Erik Dassi; Lorenzo Montanaro
Journal:  Genome Biol       Date:  2022-08-22       Impact factor: 17.906

5.  Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells.

Authors:  Carlota Oleaga; Carlos J Ciudad; Véronique Noé; Maria Izquierdo-Pulido
Journal:  Oxid Med Cell Longev       Date:  2012-08-07       Impact factor: 6.543

6.  Telomerase downregulation induces proapoptotic genes expression and initializes breast cancer cells apoptosis followed by DNA fragmentation in a cell type dependent manner.

Authors:  Blazej Rubis; Hanna Holysz; Marta Gladych; Ewa Toton; Anna Paszel; Natalia Lisiak; Mariusz Kaczmarek; Johann Hofmann; Maria Rybczynska
Journal:  Mol Biol Rep       Date:  2013-05-16       Impact factor: 2.316

7.  A genome-wide detection of selection signatures in conserved and commercial pig breeds maintained in Poland.

Authors:  Artur Gurgul; Igor Jasielczuk; Katarzyna Ropka-Molik; Ewelina Semik-Gurgul; Klaudia Pawlina-Tyszko; Tomasz Szmatoła; Magdalena Szyndler-Nędza; Monika Bugno-Poniewierska; Tadeusz Blicharski; Karolina Szulc; Ewa Skrzypczak; Jędrzej Krupiński
Journal:  BMC Genet       Date:  2018-10-22       Impact factor: 2.797

8.  STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1.

Authors:  Zhaoqing Li; Cong Chen; Lini Chen; Dengdi Hu; Xiqian Yang; Wenying Zhuo; Yongxia Chen; Jingjing Yang; Yulu Zhou; Misha Mao; Xun Zhang; Ling Xu; Siwei Ju; Jun Shen; Qinchuan Wang; Minjun Dong; Shuduo Xie; Qun Wei; Yunlu Jia; Jichun Zhou; Linbo Wang
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.